Gala-diner schreef op 1 mei 2019 07:05:
De emissie is al geslaagd, volgende stap is een partner-deal.
The company therefore needs to find more cash, with partnering or an equity raise at the top of the agenda, the chief exec said.
He maintained that there was still interest from potential collaborators, despite the mounting casualty list of Alzheimer’s projects, most recently Roche’s anti-beta amyloid antibody crenezumab.
Although Probiodrug is also targeting amyloid, the company might benefit from taking a slightly different approach. PQ912 is a small-molecule inhibitor of glutaminyl cyclase, the enzyme that converts beta-amyloid into what the company calls the toxic pGlu-Abeta form.
The most similar project in development is Lilly’s LY3002813, an antibody that binds directly to pGlu-Abeta. Notably, Lilly kept faith with this project when it cut back its Alzheimer’s pipeline last year, something Mr Dauer said he was pleased about because it validated Probiodrug’s strategy.